Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01903811 · OUTCOME

Overall Survival Crossover Group

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma · Source last updated 2024-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From date of crossover to date of death due to any cause, assessed up to 3 years from randomization

What was measured

Assessed in the crossover arm using the method of Kaplan Meier.

Groups in this outcome

Crossover Arm

Patients on Arm 1 that progress after the start of course 2 and prior to completion of 12 courses receive 20 mg dexamethasone IV and high-dose (56 mg/m\^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 additional courses in the absence of disease progression or unacceptable toxicity. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Crossover Arm16

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Crossover Arm15Not reported527Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5
        upper Limit
        27
        value
        15
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    units
    Participants
description
Assessed in the crossover arm using the method of Kaplan Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients on Arm 1 that progress after the start of course 2 and prior to completion of 12 courses receive 20 mg dexamethasone IV and high-dose (56 mg/m\^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 additional courses in the absence of disease progression or unacceptable toxicity. Carfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies
    id
    OG000
    title
    Crossover Arm
param Type
MEDIAN
reporting Status
POSTED
time Frame
From date of crossover to date of death due to any cause, assessed up to 3 years from randomization
title
Overall Survival Crossover Group
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice